Improving human health everywhere.

Science without fear.

 

Leslie J. De Groot MD, 1928-2018

Breaking News: FDA awards $1 million to EpiVax, CUBRC, to assess generic peptide drugs

 

 

PANDA: The Newest Product at EpiVax

EpiVax Oncology Completes a $1.2M Bridge Financing

EpiVax Opens New Headquarters and Celebrates 20 Years of Fearless Science

 

 

$325K NIH Grant to EpiVax to Enable Development of Personalized Risk Assessment Tool for Enzyme Replacement Therapy in Pompe Disease

We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines. For a recent interview highlighting our CEO’s latest ideas, click on the video:

Discover

We take pride in our ability to put our combined intelligence, experience, and creativity to work to improve human health. Open minds, creative thought and natural curiosity lead to paradigm shifts. Contact us today to learn more.

Corporate Office/Laboratory:
EpiVax, Inc.

188 Valley Street, Suite 424, Providence, RI 02909 USA
ph: 401.272.2123 fax: 401.272.7562